Αρχική World News Immune-Modulating SBRT Plus Anti-PD-L1 May Convert Immune-Cold ER-positive, HER2-negative EBC Into More... World News Immune-Modulating SBRT Plus Anti-PD-L1 May Convert Immune-Cold ER-positive, HER2-negative EBC Into More Inflamed Tumours and Improve Response Από Ogkologos - 3 Αυγούστου, 2026 213 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the Neo-CheckRay study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Researchers Discover Genetic Marker That Increases Risk Of Premenopausal Breast Cancer 2 Αυγούστου, 2019 Reused, Reheated Cooking Oil May Trigger Breast Cancer Progression, Metastasis 23 Απριλίου, 2019 Cooperativity of BRAF/MAPK Pathway Inhibition and Immune Checkpoint Blockade in Patients... 3 Φεβρουαρίου, 2023 Qué debo saber sobre los programas de emparejamiento de ensayos clínicos... 28 Νοεμβρίου, 2023 Φόρτωση περισσοτέρων HOT NEWS Maintenance Olaparib in Elderly Patients With a Germline BRCA Mutation and... Long-Term Clinical Benefit with Nivolumab Plus Ipilimumab Extends Beyond Treatment Discontinuation... Safety and Antitumour Activity of Setidegrasib in Patients with Previously Treated... A Pet Pug Helped Two Sisters Realize They Both Had Breast...